Janssen Biotech, one of Johnson & Johnson's pharma companies, has announced the FDA approval of its ulcerative colitis drug, Simponi for use in the US. The FDA has approved Simponi (golimumab) for the ...

Global specialty, generic and consumer healthcare medicines company STADA and Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative ...

First Anti-TNF Infusion Therapy Approved in More Than a Decade for Patients Living with Moderately to Severely Active Rheumatoid Arthritis "Phase 3 data showed treatment with SIMPONI ARIA plus ...

German generics and consumer healthcare major STADA Arzneimittel and China’s Bio-Thera Solutions, a commercial-stage ...

The European Commission has approved STADA and Bio-Thera Solutions’ Gotenfia, a biosimilar to Johnson & Johnson’s Simponi.

Janssen Biotech announced new five-year data from three pivotal Phase 3 studies evaluating Simponi (golimumab) 50mg administered subcutaneously once every four weeks in the treatment of moderately to ...

REYKJAVIK, Iceland, April 24, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, ...

HORSHAM, Pa., Sept. 30, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA ® ...

Simponi and Simponi Aria (golimumab) can cause mild to serious side effects. A more common side effect includes upper respiratory infection. If side effects from the drug become difficult to tolerate, ...

If needed, Simponi Aria may be stored at room temperature up to 77⁰F (25⁰C) for a maximum single period of 30 days in the original carton to protect from light. Once Simponi Aria has been stored at ...